Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis

Bobryshev, Yuri V.; Ivanova, Ekaterina A.; Chistiakov, Dimitry A.; Nikiforov, Nikita G.; Orekhov, Alexander N.

doi:10.1155/2016/9582430

Cited by 276 publications

(228 citation statements)

References 98 publications

(118 reference statements)

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…Macrophages in atherosclerotic lesions actively participate in lipoprotein ingestion, and their accumulation gives rise to the formation of foam cells filled with lipid droplets (Table 1) (84). Accumulation of foam cells in the lesions results in lipid storage and growth of atherosclerotic plaque.…”

Section: Maresins Role In the Clearance Of Atherosclerotic Inflammationmentioning

confidence: 99%

Unified nexus of macrophages and maresins in cardiac reparative mechanisms

Jadapalli

Halade

2018

FASEB j.

View full text Add to dashboard Cite

Macrophages are immune-sensing "big eater" phagocytic cells responsible for an innate, adaptive, and regenerative response. After myocardial infarction, macrophages predominantly clear the deceased cardiomyocyte apoptotic or necrotic neutrophils to develop a regenerative and reparative program with the activation of the lipoxygenase-mediated maresin (MaR) metabolome at the site of ischemic injury. The specialized proresolving molecule and macrophage mediator in resolving inflammation, MaR-1, produced by human macrophages, has potent defining effects that limit polymorphonuclear neutrophil infiltration, enhance uptake of apoptotic PMNs, regulate inflammation resolution and tissue regeneration, and reduce pain. In addition to proresolving and anti-inflammatory actions, MaR-1 displays potent tissue regenerative effects in stroke and is an antinociceptive. Macrophages actively participate in the biosynthesis of bioactive MaR-2, which exhibits anti-inflammatory, proresolving, and atherosclerotic effects. A new class of macrophage-derived molecules, MaR conjugates in tissue regeneration, is identified that regulates phagocytosis and the repair and regeneration of damaged tissue. The presented review provides a current summary of the effect of MaR in resolution pathophysiology, with relevance to a cardiac repair program.-Jadapalli, J. K., Halade, G. V. Unified nexus of macrophages and maresins in cardiac reparative mechanisms.

show abstract

Section: Maresins Role In the Clearance Of Atherosclerotic Inflammationmentioning

confidence: 99%

Unified nexus of macrophages and maresins in cardiac reparative mechanisms

Jadapalli

Halade

2018

FASEB j.

View full text Add to dashboard Cite

show abstract

“…Aside from autoimmune diseases, MMR has been investigated as a target for atherosclerosis because it is known that macrophages also play an important role in the formation of vulnerable plaques and foam cells in atherosclerosis . For example, M1 macrophages (pro‐inflammatory macrophages) are involved in lipid accumulation and inflammatory responses, while M2 macrophages (alternatively activated macrophages) are associated with plaque stabilization and inflammation resolution . Varasteh et al.…”

Section: Targeting Surface Markers On Immune Cellsmentioning

confidence: 99%

Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases

Lee

Cai

2018

ChemBioChem

View full text Add to dashboard Cite

Chronic inflammatory diseases are often progressive, resulting not only in physical damage to patients but also social and economic burdens, making early diagnosis of them critical. Nuclear medicine techniques can enhance the detection of inflammation by providing functional as well as anatomical information when combined with other modalities such as magnetic resonance imaging, computed tomography or ultrasonography. Although small molecules and peptides were mainly used for the treatment and imaging of chronic inflammatory diseases in the past, antibodies and their fragments have also been emerging for chronic inflammatory diseases as they show high specificity to their targets and can have various biological half‐lives depending on how they are engineered. In addition, imaging with antibodies or their fragments can visualize the in vivo biodistribution of the probes or help monitor therapeutic responses, thereby providing physicians with a greater understanding of drug behavior in vivo and another means of monitoring their patients. In this review, we introduce various targets and radiolabeled antibody‐based probes for the molecular imaging of chronic inflammatory diseases in preclinical and clinical studies. Targets can be classified into three different categories: 1) cell‐adhesion molecules, 2) surface markers on immune cells, and 3) cytokines or enzymes. The limitations and future directions of using radiolabeled antibodies for imaging inflammatory diseases are also discussed.

show abstract

“…In response, these endothelial cells express more pro‐inflammatory chemokines and adhesion molecules, and are more susceptible to monocyte adhesion . Circulating lipoproteins are more likely to penetrate the arterial wall and accumulate in the subendothelial proteoglycan‐rich layer within the intima . VCAM‐1 is the most common biomarker targeted by bio‐nanomaterials for delivery to atherosclerotic plaques (Table S1, Supporting Information) .…”

Section: Biological Targets and Animal Models For Atherosclerotic Nanmentioning

confidence: 99%

Recent Advances in Managing Atherosclerosis via Nanomedicine

Chan

Zhang

Cheng

et al. 2017

Small

View full text Add to dashboard Cite

Atherosclerosis, driven by chronic inflammation of the arteries and lipid accumulation on the blood vessel wall, underpins many cardiovascular diseases with high mortality rates globally, such as stroke and ischemic heart disease. Engineered bio-nanomaterials are now under active investigation as carriers of therapeutic and/or imaging agents to atherosclerotic plaques. This Review summarizes the latest bio-nanomaterial-based strategies for managing atherosclerosis published over the past five years, a period marked by a rapid surge in preclinical applications of bio-nanomaterials for imaging and/or treating atherosclerosis. To start, the biomarkers exploited by emerging bio-nanomaterials for targeting various components of atherosclerotic plaques are outlined. In addition, recent efforts to rationally design and screen for bio-nanomaterials with the optimal physicochemical properties for targeting plaques are presented. Moreover, the latest preclinical applications of bio-nanomaterials as carriers of imaging, therapeutic, or theranostic agents to atherosclerotic plaques are discussed. Finally, a mechanistic understanding of the interactions between bio-nanomaterials and the plaque ("athero-nano" interactions) is suggested, the opportunities and challenges in the clinical translation of bio-nanomaterials for managing atherosclerosis are discussed, and recent clinical trials for atherosclerotic nanomedicines are introduced.

show abstract

Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis

Cited by 276 publications

References 98 publications

Unified nexus of macrophages and maresins in cardiac reparative mechanisms

Unified nexus of macrophages and maresins in cardiac reparative mechanisms

Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases

Recent Advances in Managing Atherosclerosis via Nanomedicine

Contact Info

Product

Resources

About